COMBINATION THERAPY OF HYPERTENSION — A RELIABLE WAY TO TARGET ACHIEVE
https://doi.org/10.20996/1819-6446-2010-6-6-859-864
Abstract
Data of evidence-based cardiology and clinical guidelines that define the position of combined therapy to achieve the targets of hypertension (HT) treatment (achievement and maintenance of the target blood pressure (BP) level, protection of the target organs, improvement of the quality of life in hypertensive patients) are presented in the article. The advantages of rational combined therapies (potentiation of antihypertensive effect, reduction of a number of adverse events) are considered. Studies of therapeutic efficacy and safety of combined antihypertensive therapy based on generics are important. The advantages of combined therapy in achievement of target BP levels are presented on example of comparative study of new generic and original amlodipine in patients with HT of 1-2 degrees. Target BP level was reached respectively in 90% and 97% of patients with HT in groups of generic and original amlodipine combined with generic lisinopril and hydrochlorothiazide. Safety profile was acceptable. This confirms the high efficacy of amlodipine + lisinopril + hydrochlorothiazide combination, including one on the basis of generics.
About the Authors
Yu. V. Lukina
State Research Center for Preventive Medicine
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
Petroverigsky per. 10, Moscow, 101990
Trubetskaya ul. 8-2, Moscow, 119991
S. Yu. Martsevich
State Research Center for Preventive Medicine
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
Petroverigsky per. 10, Moscow, 101990
Trubetskaya ul. 8-2, Moscow, 119991
References
1. Oganov R.G. Prevention of cardiovascular diseases: opportunities for health protection. Kardiovaskuljarnaja terapija i profilaktika 2002; 1: 5–9. Russian (Оганов Р.Г. Профилактика сердечно-сосудистых заболеваний: возможности практического здравоохранения. Кардиоваскулярная терапия и профилактика 2002; 1: 5–9).
2. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42(6):1206— 52.
3. Shalnova S.A., Balanova Yu.A., Konstantinov V.V. et al. Arterial hypertension: prevalence, awareness, anti-hypertensive pharmaceutical treatment, treatment effectiveness in Russian population. Rossiyskiy kardiologicheskiy zhurnal 2006; 4: 45—50. Russian (Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006; 4: 45—50).
4. Moser M. Clinical management of Hypertension. Fourth edition. Caddo: Professional Communications Inc.; 1999.
5. ManciaG.,De Backer G.,Dominiczak A. et al.2007Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87.
6. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 Suppl 2:S1-113.
7. National guidelines for diagnosis and treatment of hypertension. Kardiovaskuljarnaja terapija i profilaktika 2008; 7(6) Prilozhenie 2; 1-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная терапия и профилактика 2008; 7(6)Приложение 2; 1-32).
8. Opie L.H., Messerli F.H.Combination Drug Therapy forHypertension. NY, Philadelphia: Lippincott-Raven Publishers; 1997.
9. Messerli FH Clinican’s manual on combination therapy and hypertension SP, 2003, pp.62
10. Sica D., Ripley E. Low-dose fixed-combination antihypertensive therapy in hypertension. In: Oparil S., Weber M., editors. Hypertension: a companion to Brenner and Rector's the kidney. Philadelphia, (PA): WB Saunders Company, 2000: 497-504
11. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood–pressure lowering and low– dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351(9118):1755–62
12. HOPE study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342(3):145-53
13. Dahlöf B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906
14. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Finalresults of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265(24):3255-64
15. Olsson G., Tuomilehto J., Berglund G. et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991;4:151-8
16. Dahlöf B., Lindholm L.H., Hansson L. et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338(8778):1281-5
17. Pepine C., Handberg-Thurmond E. et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): An internet-based randomixed trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998 Nov;32(5):1228-37.
18. IPPPSHCollaborative Group. Cardiovascularrisk and risk factors in a randomized trial of treatment based on the beta–blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3(4): 379–392.
19. Dahlöf B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995–1003
20. Dickerson J.E., Hingorani A.D., Ashby M.J. et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353(9169):2008-13
21. Meshkovskiy A.P. Place of generics in the pharmaceutical supply. Farmateka 2003; 3:103-104. Russian (Мешковский А.П. Место дженериков в лекарственном обеспечении. Фарматека 2003; 3:103- 104).
22. Martsevich S.Yu., Kutishenko N.P., Dmitrieva N.A., Belolipetskaya V.G. Choosing a medication in cardiology: what are the guiding points for a practitioner? Kardiovaskulyarnaya terapiya i profilaktika 2004; 4: 77–82. Russian (Марцевич С.Ю., Кутишенко Н.П., Дмитриева Н.А., Белолипецкая В.Г. Выбор лекарственного препарата в кардиологии: на что должен ориентироваться практический врач? Кардиоваскулярная терапия и профилактика 2004; 4: 77–82).
23. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 863 - Thirty-fourth Report; 1996, pp. 114-154. Available on: http://apps.who.int/medicinedocs/pdf/s5516e/s5516e.pdf
24. International comparator products for bioequivalence testing. WHO Drug Information 1999; 13(3): 158-162.
25. Vikulova S. Bioequivalence and generics: were made for each other. Remedium 1999; 12: 30-2. Russian (Викулова С. Биоэквивалентность и дженерики: созданы друг для друга. Ремедиум 1999; 12: 30-2)
26. Lukina J.V., Deev A.D., Dmitrieva N.A. et al. Comparative study of new drug of long acting metoprolol tartrate — Egilok retard and original drug of metoprolol succinate — Betaloc ZOK in patients with mild to moderate arterial hypertension. Rational Pharmacother Card 2005;3:35-40. Russian (Лукина Ю.В., Деев А.Д, Дмитриева Н.А. и др. Сравнительное изучение нового препарата метопролола тартрата пролонгированного действия – эгилока ретард и оригинального препарата метопролола сукцината – беталока ЗОК у больных мягкой и умеренной артериальной гипертонией. РФК 2005; 3: 35-40).
27. Martsevich S.Yu., Kutishenko N.P., Deev A.D. Therapeutic equivalence of two amlodipine preparations (original and generic) in patients with arterial hypertension. Results of a double-blind, randomized cross-over study. Rossiyskiy kardiologicheskiy zhurnal 2004; 4: 53-56. Russian (Марцевич С.Ю., КутишенкоН.П., Деев А.Д. и др. Изучение терапевтической эквивалентности двух препаратов амлодипина (оригинального и воспроизведенного) у больных артериальной гипертонией. Результаты двойного слепого рандомизированного перекрестного исследования. Российский кардиологический журнал 2004; 4: 53-56).
28. Martsevich S.Y., Lukina J.V.,Deev A.D. et al. Comparative study of combined drugs of enalapril maleate and hydrochlorothiazide: «Renipril HT» and «Co-renitec» in patients with mild to moderate arterial hypertension. Rational Pharmacother. Card. 2005;3:29-34. Russian (Марцевич С.Ю., Лукина Ю.В., Деев А.Д. и др. Сравнительное изучение комбинированных препаратов эналаприла малеата и гидрохлортиазида: «рениприла ГТ» и «ко-ренитека» у больных мягкой и умеренной АГ. РФК 2005; 3: 29-34).
29. Nedogoda S.V., Marchenko I.V., Chalyabi T.A. Comparative antihypertensive efficacy of generic ACE inhibitor enalapril-Renitec (Enap, Ednit, Invoril, Envas and Enam) and the cost of treatment in patients with hypertension.Arterial'naya gipertenziya 2000;1:52-54. Russian (Недогода С.В., Марченко И.В., Чаляби Т.А. Сравнительная антигипертензивная эффективность генериков ингибитора ангио- тензинпревращающего фермента эналаприла-ренитека (энапа, эднита, инворила, энваса и энама) и стоимость лечения у больных гипертонической болезнью. Артериальная гипертензия 2000;1:52-54).
30. Belenkov Yu.N., MareevV.Yu. on behalf ofthe Working Group study EPIGRAF. Enalapril plus Indapamide in the treatment of stable arterial ipertonii: efficacy and safety of a rational combination pharmacotherapy (EPIGRAF). The first results of Russian multicenter study. Serdtse 2003; 2(4): 3–7. Russian (Белен- ков Ю.Н., Мареев В.Ю. от имени рабочей группы исследования ЭПИГРАФ. Эналаприл Плюс Индапамид в лечении стабильной артериальной ипертонии: оценка эффективности и безопасности Рациональной комбинированной Фармакотерапии (ЭПИГРАФ).Первые результаты Российского многоцентрового исследования. Сердце 2003; 2(4): 3–7)
31. Chazova I.E., Belenkov Yu.N. ROSA — The Russian study on the optimal reduction in blood pressure. Sistemnye gipertenzii 2004; 6(2): 13-28. Russian (Чазова И.Е., Беленков Ю.Н. РОСА — Российское исследование по Оптимальному Снижению Артериального давления. Системные гипертензии 2004; 6(2): 13-28)
32. Martsevich S.Yu., Kutishenko N.P., Shilova E.V. et al. on behalf of the working group on the study "KAMELIYA". Carvedilol in patients with arterial hypertension and overweight / obesity. Results of the study "KAMELIYA". Trudnyy patsient 2009; (4-5): 19–23. Russian (Марцевич С.Ю., КутишенкоН.П., Шилова Е.В. и соавт. от имени рабочей группыпо проведению исследования «КАМЕЛИЯ». Карведилол в лечении пациентов с артериальной гипертонией и избыточной массой тела/ожирением. Результаты исследования «КАМЕЛИЯ». Трудный пациент 2009; (4-5): 19–23).
33. Martsevich S.Yu., Dmitrieva N.A., Deev A.D. et al. Achievement of target blood pressure level in hypertensive patients with amlodidine: original drug versus generic. Rational Pharmacother Cardiol 2009;(6):35-40. Russian (Марцевич С.Ю., Дмитриева Н.А., Деев А.Д. и соавт. Достижение целевого уровня артериального давления у больных артериальной гипертонией: оригинальный и дженерический препараты амлодипина. РФК 2009; 6: 35-40).
Review
For citations:
Lukina Yu.V., Martsevich S.Yu. COMBINATION THERAPY OF HYPERTENSION — A RELIABLE WAY TO TARGET ACHIEVE. Rational Pharmacotherapy in Cardiology. 2010;6(6):859-864. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-6-859-864
Views:
866
Email this article 